AR067562A1 - Compuestos heterociclicos inhibidores de kinasa - Google Patents
Compuestos heterociclicos inhibidores de kinasaInfo
- Publication number
- AR067562A1 AR067562A1 ARP080103052A ARP080103052A AR067562A1 AR 067562 A1 AR067562 A1 AR 067562A1 AR P080103052 A ARP080103052 A AR P080103052A AR P080103052 A ARP080103052 A AR P080103052A AR 067562 A1 AR067562 A1 AR 067562A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- amino
- aryl
- hetero
- aryloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Reivindicacion 1: Un compuesto de la formula (A): en donde: el anillo AD es un anillo heterocíclico aromático 5,6-bicíclico, en donde A es un anillo heterocíclico aromático de 5 miembros que contiene uno o mas átomos de O, S y N del anillo fusionado con el anillo D, el cual es un anillo de fenilo o un anillo heterocíclico aromático de 6 miembros que contiene uno, dos o tres átomos de nitrogeno del anillo, en donde el anillo AD esta sustituido por R2, R3, R4, y R5; E es un arilo de 6 a 10 átomos de carbono, un hetero-arilo de 5 a 10 miembros, o halogeno, en donde los anillos están opcionalmente sustituidos por R6, R7 y R8; Q es O o S; R1 se selecciona a partir del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido alcoxilo, alcoxilo sustituido amino, amino sustituido, arilo, arilo sustituido, hetero-arilo, hetero-arilo sustituido, heterociclilo, cicloalquilo, cicloalquilo sustituido, heterociclilo sustituido, ariloxilo, ariloxilo sustituido, hetero-ariloxilo, hetero-ariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, y alquil-amino; R2 Y R3 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxilo, alcoxilo sustituido, arilo, arilo sustituido, hetero-arilo, hetero-arilo sustituido, heterociclilo, cicloalquilo, cicloalquilo sustituido, heterociclilo sustituido, ariloxilo, ariloxilo sustituido, hetero-ariloxilo, hetero-ariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, acilo, acilamino, aciloxilo, amino, amino sustituido, amino-carbonilo, amino-tiocarbonilo, amino-carbonil-amino, amino-tiocarbonil-amino, amino-carboniloxilo, amino-sulfonilo, amino-sulfoniloxilo, amino-sulfonil-amino, amidino, carboxilo, carboxil-éster, (carboxil-éster)-amino, (carboxil-éster)-oxilo, ciano, halogeno, hidroxilo, nitro, SO3H, sulfonilo, sulfonilo sustituido, sulfoniloxilo, tioacilo, tiol, tioalquilo, y tioalquilo sustituido; R4 y R5 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, halogeno, ciano, nitro, amino, amino sustituido, alcoxilo, alcoxilo sustituido, alquilo, y alquilo sustituido; R6 se selecciona a partir del grupo que consiste en hidrogeno, halogeno, ciano, nitro, alcoxilo, alcoxilo sustituido, alquilo, y alquilo sustituido; y R7 y R8 se seleccionan independientemente a partir del grupo que consiste en hidrogeno, alquilo, alquilo sustituido, alquenilo, alquenilo sustituido, alquinilo, alquinilo sustituido, alcoxilo, alcoxilo sustituido, arilo, arilo sustituido, hetero-arilo, hetero-arilo sustituido, heterociclilo, cicloalquilo, cicloalquilo sustituido, heterociclilo sustituido, ariloxilo, ariloxilo sustituido, hetero-ariloxilo, hetero-ariloxilo sustituido, heterocicliloxilo, heterocicliloxilo sustituido, cicloalquiloxilo, cicloalquiloxilo sustituido, acilo, aciloxilo, amino-carbonilo, amino-tiocarbonilo, amino-tiocarbonil-amino, amino-carboniloxilo, amino-sulfonilo, amino-sulfoniloxilo, amino-sulfonil-amino, amidino, carboxilo, carboxil-éster, (carboxil-éster)-oxilo, ciano, halogeno, hidroxilo, nitro, SO3H, sulfonilo, sulfonilo sustituido, sulfoniloxilo, tioacilo, tiol, tioalquilo, y tioalquilo sustituido; o R7 y R8 junto con los átomos del anillo con los que están unidos, forman un grupo carbocíclico o heterocíclico de 5 a 8 miembros. Compuestos inhibidores de cinasa de fosíatidil-inositol (Pl)-3, sus sales farmacéuticamente aceptables, y pro-fármacos de los mismos; composiciones de los nuevos compuestos, ya sea solos o bien en combinacion con cuando menos un agente terapéutico adicional, con un vehículo farmacéuticamente aceptable y utilizacion de los compuestos, ya sea solos o bien en combinacion con cuando menos un agente terapéutico adicional, en la profilaxis o el tratamiento de enfermedades proliferativas caracterizadas por la actividad anormal de los factores de crecimiento, las cinasas de proteína serina/treonina, y las cinasas de fosfolípidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07112688 | 2007-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR067562A1 true AR067562A1 (es) | 2009-10-14 |
Family
ID=38800784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103052A AR067562A1 (es) | 2007-07-18 | 2008-07-16 | Compuestos heterociclicos inhibidores de kinasa |
Country Status (15)
Country | Link |
---|---|
US (1) | US8053574B2 (es) |
EP (1) | EP2178868A1 (es) |
JP (1) | JP2010533680A (es) |
KR (1) | KR20100049073A (es) |
CN (1) | CN101801966A (es) |
AR (1) | AR067562A1 (es) |
AU (1) | AU2008277628B2 (es) |
BR (1) | BRPI0813831A2 (es) |
CA (1) | CA2693232A1 (es) |
CL (1) | CL2008002097A1 (es) |
EA (1) | EA201000130A1 (es) |
MX (1) | MX2010000716A (es) |
PE (1) | PE20090492A1 (es) |
TW (1) | TW200908969A (es) |
WO (1) | WO2009010530A1 (es) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
SG174086A1 (en) | 2006-08-30 | 2011-09-29 | Cellzome Ltd | Triazole derivatives as kinase inhibitors |
TW200911798A (en) | 2007-08-02 | 2009-03-16 | Amgen Inc | PI3 kinase modulators and methods of use |
SG186040A1 (en) | 2007-11-27 | 2012-12-28 | Cellzome Ltd | Amino triazoles as pi3k inhibitors |
JP5520831B2 (ja) * | 2007-12-19 | 2014-06-11 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
WO2009129211A1 (en) | 2008-04-16 | 2009-10-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of phosphatidylinositol 3-kinase |
EP2444403A1 (en) | 2008-04-18 | 2012-04-25 | Shionogi Co., Ltd. | Heterocyclic compound having inhibitory activity on PI3K |
JP5599783B2 (ja) | 2008-05-30 | 2014-10-01 | アムジエン・インコーポレーテツド | Pi3キナーゼの阻害薬 |
WO2010010188A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
WO2010010186A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
SG190568A1 (en) | 2008-09-26 | 2013-06-28 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
CN102307847A (zh) | 2008-12-24 | 2012-01-04 | 第一三共株式会社 | 茚满基化合物 |
CN102307852B (zh) | 2008-12-24 | 2013-12-18 | 第一三共株式会社 | 环状胺化合物 |
WO2010092015A1 (en) * | 2009-02-10 | 2010-08-19 | Cellzome Limited | Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors |
WO2010108074A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Inhibitors of pi3 kinase |
TW201103943A (en) | 2009-04-27 | 2011-02-01 | Shionogi & Co | Urea derivative having pi3k inhibitory activity |
US8367830B2 (en) | 2009-05-20 | 2013-02-05 | Cellzome Ag | Methods for the identification of phosphatidylinositol kinase interacting molecules and for the purification of phosphatidylinositol kinase proteins |
EP2438066A2 (en) | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
MX2012000178A (es) * | 2009-07-02 | 2012-02-28 | Novartis Ag | 2-carboxamida-cicloamino-ureas utiles como inhibidores de pi3k. |
EP2343295A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridine derivates |
EP2343297A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Triazolopyridines |
EP2343294A1 (en) * | 2009-11-30 | 2011-07-13 | Bayer Schering Pharma AG | Substituted triazolopyridines |
TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt拮抗劑及治療和篩選方法 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8513291B2 (en) * | 2010-06-01 | 2013-08-20 | Angion Biomedica Corp. | Cytochrome P450 inhibitors and uses thereof |
UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
AP3491A (en) * | 2011-04-21 | 2015-12-31 | Bayer Ip Gmbh | Triazolopyridines |
WO2012160029A1 (en) | 2011-05-23 | 2012-11-29 | Bayer Intellectual Property Gmbh | Substituted triazolopyridines |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
UA112096C2 (uk) | 2011-12-12 | 2016-07-25 | Байєр Інтеллектуал Проперті Гмбх | Заміщені триазолопіридини та їх застосування як інгібіторів ttk |
CN104284896B (zh) | 2012-03-14 | 2016-06-01 | 拜耳知识产权有限责任公司 | 取代的咪唑并哒嗪 |
PE20150354A1 (es) | 2012-07-10 | 2015-03-21 | Bayer Pharma AG | Metodos para preparar triazolopiridinas sustituidas |
WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
US20150258127A1 (en) | 2012-10-31 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
CN104870017B (zh) | 2012-11-08 | 2020-08-14 | 理森制药股份公司 | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Wnt経路インヒビターによる処置の方法およびモニタリング |
WO2014198647A2 (en) | 2013-06-11 | 2014-12-18 | Bayer Pharma Aktiengesellschaft | Prodrug derivatives of substituted triazolopyridines |
WO2015039333A1 (en) * | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
ME03580B (me) | 2014-02-13 | 2020-07-20 | Incyte Corp | Ciklopropilamini kao lsd1 inhibitori |
CA2939082C (en) | 2014-02-13 | 2022-06-07 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
WO2015134171A1 (en) | 2014-03-06 | 2015-09-11 | Takeda Pharmaceutical Company Limited | Heteroarylamide inhibitors of tbk1 |
WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
CR20180152A (es) | 2015-08-12 | 2018-08-09 | Incyte Corp | Sales de un inhibidor de lsd1 |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
MX2018012901A (es) | 2016-04-22 | 2019-06-06 | Incyte Corp | Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1). |
BR112019010511A2 (pt) | 2016-11-23 | 2019-09-17 | Bayer Ag | derivados de heterociclo bicíclico fundido como pesticidas |
US10774086B2 (en) * | 2016-11-28 | 2020-09-15 | Bristol-Myers Squibb Company | GSK-3 inhibitors |
PT3692023T (pt) | 2017-10-02 | 2023-08-23 | 1St Biotherapeutics Inc | Compostos de benzotiazol e métodos que os utilizam para tratar distúrbios neurodegenerativos |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶 |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
EP3818063A1 (en) | 2018-07-05 | 2021-05-12 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
WO2020170206A1 (en) | 2019-02-22 | 2020-08-27 | 1ST Biotherapeutics, Inc. | Imidazopyridinyl compounds and use thereof for treatment of proliferative disorders |
US20220160902A1 (en) * | 2019-03-07 | 2022-05-26 | 1ST Biotherapeutics, Inc. | [18F]-Labeled Benzothiazole Derivative As PET Radiotracer |
US10385046B1 (en) | 2019-03-19 | 2019-08-20 | 1ST Biotherapeutics, Inc. | Processes for preparing benzothiazol compounds and methods of using the same for treating neurodegenerative disorders |
CN111116580B (zh) * | 2019-12-27 | 2022-08-23 | 上海应用技术大学 | 一种尼麦角林的改进制备方法 |
WO2023180976A1 (en) * | 2022-03-25 | 2023-09-28 | 1ST Biotherapeutics, Inc. | Indazoles as hematopoietic progenitor kinase 1 (hpk1) inhibitors and methods for using same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0261459A3 (de) * | 1986-09-09 | 1988-05-11 | Nihon Tokushu Noyaku Seizo K.K. | Neue N-Benzothiazolylamide |
CA2386813C (en) * | 1999-10-08 | 2008-09-02 | Grunenthal Gmbh | Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring |
IL151045A0 (en) * | 2000-02-07 | 2003-04-10 | Abbott Gmbh & Co Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
JP2007529496A (ja) * | 2004-03-19 | 2007-10-25 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体 |
MXPA06013022A (es) | 2004-05-12 | 2007-01-23 | Squibb Bristol Myers Co | Antagonistas de urea de receptor p2y1 utiles en el tratamiento de condiciones tromboticas. |
US7636348B2 (en) * | 2004-06-30 | 2009-12-22 | Bettis Sonny R | Distributed IP architecture for telecommunications system with video mail |
US7524860B2 (en) | 2004-10-07 | 2009-04-28 | Pfizer Inc. | Antibacterial agents |
US7576090B2 (en) * | 2004-12-27 | 2009-08-18 | 4Sc Ag | Benzazole analogues and uses thereof |
-
2008
- 2008-07-16 KR KR1020107003426A patent/KR20100049073A/ko not_active Application Discontinuation
- 2008-07-16 MX MX2010000716A patent/MX2010000716A/es not_active Application Discontinuation
- 2008-07-16 PE PE2008001205A patent/PE20090492A1/es not_active Application Discontinuation
- 2008-07-16 CN CN200880107620A patent/CN101801966A/zh active Pending
- 2008-07-16 AU AU2008277628A patent/AU2008277628B2/en not_active Expired - Fee Related
- 2008-07-16 EA EA201000130A patent/EA201000130A1/ru unknown
- 2008-07-16 BR BRPI0813831-1A2A patent/BRPI0813831A2/pt not_active IP Right Cessation
- 2008-07-16 US US12/669,536 patent/US8053574B2/en not_active Expired - Fee Related
- 2008-07-16 WO PCT/EP2008/059298 patent/WO2009010530A1/en active Application Filing
- 2008-07-16 EP EP08775120A patent/EP2178868A1/en not_active Withdrawn
- 2008-07-16 CA CA2693232A patent/CA2693232A1/en not_active Abandoned
- 2008-07-16 JP JP2010516500A patent/JP2010533680A/ja not_active Withdrawn
- 2008-07-16 AR ARP080103052A patent/AR067562A1/es not_active Application Discontinuation
- 2008-07-17 CL CL2008002097A patent/CL2008002097A1/es unknown
- 2008-07-17 TW TW097127181A patent/TW200908969A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2178868A1 (en) | 2010-04-28 |
JP2010533680A (ja) | 2010-10-28 |
US8053574B2 (en) | 2011-11-08 |
US20100197682A1 (en) | 2010-08-05 |
WO2009010530A1 (en) | 2009-01-22 |
BRPI0813831A2 (pt) | 2015-01-06 |
CN101801966A (zh) | 2010-08-11 |
EA201000130A1 (ru) | 2010-08-30 |
CA2693232A1 (en) | 2009-01-22 |
PE20090492A1 (es) | 2009-05-27 |
AU2008277628B2 (en) | 2012-03-15 |
CL2008002097A1 (es) | 2009-02-20 |
AU2008277628A1 (en) | 2009-01-22 |
KR20100049073A (ko) | 2010-05-11 |
MX2010000716A (es) | 2010-03-26 |
TW200908969A (en) | 2009-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR067562A1 (es) | Compuestos heterociclicos inhibidores de kinasa | |
DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
AR074002A1 (es) | Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir) | |
PE20191744A1 (es) | Derivados de tirosinamida como inhibidores de rho-quinasa | |
AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
AR059087A1 (es) | Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas. | |
EA201001013A1 (ru) | Бис(сульфониламино)производные для применения в терапии | |
CR20140216A (es) | 5,7-imidazo[1,2-c]pirimidinas sustituidas | |
NI201000085A (es) | Derivados bis - (sulfonilamino) en terapia 066. | |
AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
UY29246A1 (es) | Nuevos compuestos | |
AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
AR072791A1 (es) | DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER. | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
BRPI0707491B8 (pt) | compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas | |
AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
AR062745A1 (es) | 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa | |
ES2577382T3 (es) | Nuevos derivados de tienopirimidina, procedimientos para su preparación, y sus usos terapéuticos | |
AR082109A1 (es) | Derivados de bipiridilo | |
EA201101566A1 (ru) | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ | |
ECSP089019A (es) | Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa | |
RU2008112661A (ru) | Бензодиазепины в качестве ингибиторов hcv | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |